The convergence of generative artificial intelligence (AI) platforms and automated laboratory systems is ushering in a new era of drug discovery, in which a plain-language prompt can initiate a fully autonomous, end-to-end drug development program. This article explores the recent evolution of AI technologies and presents a “prompt-to-drug” pipeline, where AI not only generates novel hypotheses and designs optimized drug candidates but also orchestrates synthesis, validation, and clinical planning in a closed-loop system. By highlighting key breakthroughs, case studies, and the technological infrastructure required for this paradigm shift, we outline a vision for scalable, efficient, and unbiased drug discovery.
Zhavoronkov et al. (Mon,) studied this question.